DESCRIPTION

Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials.

Topics include:

- Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors)
- Ras inhibitors
- Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors)
- Lenalidomide analogs
- New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine
- Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib)
- New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40)
- Thrombopoietic agents

Leukemias: Principles and Practice of Therapy
• Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease

• Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area

Adobe Reader
Adobe Reader

ABOUT THE AUTHOR

Dr. Stefan Faderl specializes in acute and chronic leukemias. His main areas of interest include acute lymphoblastic leukemias (ALL), acute myeloid leukemias (AML), chronic lymphocytic leukemia (CLL) and its variants, as well as chronic myeloid leukemias (CML).

Dr. Hagop M. Kantarjian is Professor of Medicine and Chairman of the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas. He specializes in leukemia and is interested in creating new treatment approaches for these diseases. He has authored and contributed to over 560 medical publications, articles, and abstracts.

For additional product details, please visit https://www.wiley.com/en-us